| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1191/0961203305LU2211OA |
| P698 | PubMed publication ID | 16218478 |
| P50 | author | Yehuda Shoenfeld | Q1515807 |
| Eiji Matsuura | Q73476759 | ||
| P2093 | author name string | K Inoue | |
| K Kobayashi | |||
| L R Lopez | |||
| P2860 | cites work | Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H) | Q24558202 |
| Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus | Q28261335 | ||
| Antibodies to beta 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus | Q28290536 | ||
| Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity | Q29617216 | ||
| Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins | Q33834184 | ||
| Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids | Q36263522 | ||
| Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition | Q37207643 | ||
| beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program | Q40693493 | ||
| Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression | Q40957024 | ||
| Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus--a meta-analysis | Q41537096 | ||
| Low density lipoprotein oxidation and its pathobiological significance | Q41566828 | ||
| Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface | Q42084495 | ||
| Omega-carboxyl variants of 7-ketocholesteryl esters are ligands for beta(2)-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages | Q44138798 | ||
| Circulating oxidized LDL forms complexes with beta2-glycoprotein I: implication as an atherogenic autoantigen | Q44300088 | ||
| Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. | Q46095021 | ||
| P433 | issue | 9 | |
| P921 | main subject | atherosclerosis | Q12252367 |
| P304 | page(s) | 736-741 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | Lupus | Q6704846 |
| P1476 | title | Oxidized LDL/beta2-glycoprotein I complexes: new aspects in atherosclerosis | |
| P478 | volume | 14 |
| Q36951073 | A novel overlap syndrome: systemic sclerosis associated with antiphospholipid syndrome--a case series |
| Q36766008 | Accelerated atherosclerosis in ApoE deficient lupus mouse models. |
| Q37709623 | Advances in immune-modulating therapies to treat atherosclerotic cardiovascular diseases |
| Q46014277 | ApoE-/-Fas-/- C57BL/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis, and osteopenia. |
| Q37791682 | Atherosclerosis and macrovascular involvement in systemic sclerosis: Myth or reality |
| Q37378106 | Atherosclerosis in autoimmune diseases |
| Q37319989 | Atherosclerosis in autoimmune rheumatic diseases-mechanisms and clinical findings |
| Q64245915 | Autoantibody detection is not recommended for chronic pancreatitis: a cross-sectional Study of 557 patients |
| Q37283009 | Autoimmune-mediated atherothrombosis |
| Q64262888 | Cardiac Manifestations of Antiphospholipid Syndrome With Focus on Its Primary Form |
| Q34081242 | Cardiovascular involvement in autoimmune diseases |
| Q26774158 | Chronic Inflammatory Diseases and Endothelial Dysfunction |
| Q37316712 | Immunogenic oxidized low-density lipoprotein/beta2-glycoprotein I complexes in the diagnostic management of atherosclerosis |
| Q33879138 | Oxidized LDL: diversity, patterns of recognition, and pathophysiology |
| Q37328097 | Pentraxins, anti-pentraxin antibodies, and atherosclerosis |
| Q37348324 | Reduced beta2-glycoprotein I protects macrophages from ox-LDL-induced foam cell formation and cell apoptosis |
| Q53203652 | Sixth meeting of the European Forum on antiphospholipid antibodies. How to improve the understanding of the antiphospholipid syndrome? |
| Q42068831 | TGF-β1 induces human aortic vascular smooth muscle cell phenotype switch through PI3K/AKT/ID2 signaling |
| Q43251127 | Vaccination, atherosclerosis and systemic lupus erythematosus |
Search more.